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Abstract
Background: The 5' untranslated region (UTR) or leader sequence of simian immunodeficiency
virus (SIVmac239) is multifunctional and harbors the regulatory elements for viral replication,
persistence, gene translation, expression, and the packaging and dimerization of viral genomic RNA
(vRNA). We have constructed a series of deletions in the SIVmac239 leader sequence in order to
determine the involvement of this region in both the packaging and dimerization of viral genomic
RNA. We also assessed the impact of these deletions upon viral infectiousness, replication kinetics
and gene expression in cell lines and monkey peripheral blood mononuclear cells (PBMC).
Results: Regions on both sides of the major splice donor (SD) were found to be necessary for the
efficiency and specificity of viral genome packaging. However, stem-loop1 is critical for both RNA
encapsidation and dimerization. Downstream elements between the splice donor and the initiation
site of SIV-Gag have additive effects on RNA packaging and contribute to a lesser degree to RNA
dimerization. The targeted disruption of structures on both sides of the SD also severely impacts
viral infectiousness, gene expression and replication in both CEMx174 cells and rhesus PBMC.
Conclusion: In the leader region of SIVmac239, stem-loop1 functions as the primary determinant
for both RNA encapsidation and dimerization. Downstream elements between the splice donor
and the translational initiation site of SIV-Gag are classified as secondary determinants and play a
role in dimerization. Collectively, these data signify a linkage between the primary encapsidation
determinant of SIVmac239 and RNA dimerization.
Background
The 5' untranslated region (UTR) or leader sequence of
lentivirus possess multiple structural and functional
domains that include the regulatory elements for the ini-
tiation of reverse transcription, integration of the proviral
genome, the trans-activation of RNA transcription, and
protein translation. This region is also critical for both the
encapsidation and dimerization of viral genomic RNA
(vRNA). These latter functions act through cis-acting sig-
nals that are found within conserved structural domains
of the viral leader sequence [1-3].
In regard to vRNA packaging in human immunodefi-
ciency virus type-1 (HIV-1), the primary encapsidation
determinant or Psi core (Ψ) has been shown to be located
downstream of the major splice donor (SD), involving
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those structures that form stem loop-3 (SL3) and SL4
[4,5]. Upstream regions also have been described for their
role in RNA encapsidation, particularly SL1 and the R and
U3 regions [6]. The efficient packaging of vRNA also
requires multipartite RNA-protein interaction of the
leader RNA with the viral nucleocapsid (NC) domains of
the Gag precursor (Pr55Gag), [7-9]. Interestingly, while
HIV-1 has been shown capable of packaging the genomic
RNA of either human immunodeficiency virus type-2
(HIV-2) or simian immunodeficiency virus (SIV) [10,11],
the converse is not true, highlighting the important differ-
ences in the mechanism of RNA selection [10,12].
Although broadly comparable RNA secondary structures
have been predicted for the leader regions of HIV-1, HIV-
2 and SIV, prominent variations in sequence and structure
are evident. For example, the sequences upstream of stem-
loop 1 (SL1) in HIV-1 are 59 nucleotides long, whereas
the comparable region in SIVmac239  is 38 nucleotides
longer [13]. Similarly, the region downstream of the
major SD of SIVmac is longer than the equivalent region of
HIV-1. Functionally, this region in SIV has been shown to
have internal ribosome entry site (IRES) activity, whereas,
in the case of HIV-1, this element includes a region
encompassing both sides of the SD [14,15]. Interestingly,
HIV-1 has been shown to also encode an IRES element
within the 5'gag-coding region [16].
Contrary to that described for HIV-1, the primary packag-
ing locus (or Ψ core) of HIV-2 is located upstream of the
SD [17,18]. In SIV, work by our group and others have
described the regions 5' of the SD as important in encap-
sidation [13,19,20]. However, Poeschla et al. showed in
HIV-2 that a large deletion adjacent to the 3' SD can abro-
gate encapsidation [21]. Griffin et al demonstrated that
HIV-2, employs a co-translational mechanism of RNA
packaging whereby newly translated Gag polyprotein
interacts with vRNA while in a ribosomal translation com-
plex, thereby imparting packaging specificity [22].
Implicit in the encapsidation process of all retroviral line-
ages except the Spumoretroviruses, is the formation of a
linked RNA duplex or dimer consisting of two full-length
vRNA molecules. Early in viral assembly, two copies of the
viral genome bind at their 5' ends through non-covalent
interaction of complimentary sequences located at the ter-
minal palindrome of stem-loop 1 (SL1) [23]. This
sequence has been aptly termed the dimerization initia-
tion site (DIS) or kissing-loop domain (KLD) in the case
of HIV-1 [24,25]. The association of viral RNA with NC
protein catalyses its transition from a "immature" dimer
into an extended "mature" state, termed the dimer linkage
structure (DLS), concurrent with the maturation of nas-
cent virions [26].
The importance of RNA-RNA interactions in selective
genome packaging is based on evidence from the leader
region of HIV-1 suggesting that SL1 alone is sufficient to
initiate formation of this duplex, and enhances the rate of
dimerization  in vitro [27]. Forced evolutionary studies
have revealed interaction of the DIS/KLD with multiple
protein domains of NC as well as other regions of the Gag-
polyprotein [28]. Genome packaging is also dependent
on leader-RNA tertiary conformation. For example, in-
vitro studies with HIV-2 describe alternating RNA struc-
tures that regulate both RNA packaging and dimerization
[29-33]. However, the relationship between RNA packag-
ing and RNA dimerization is still questioned ; some
groups have proposed that different RNA structures may
lead to alternate forms of interaction [34,35]. Others have
suggested that differences among various retroviral sys-
tems may exist, lending a uniqueness to individual viruses
or groups of viruses [36].
Our group has previously described the upstream
SIVmac239 leader and its impact upon viral replication and
RNA encapsidation [13,19]. In the present study, we have
extended our analysis of several attenuated leader variants
of SIVmac239 to include the regions on either side of the
major SD, as no studies to date have investigated both
RNA encapsidation and RNA dimerization in SIV. We
show that elements on both sides of the major SD impact
both RNA packaging and dimerization, and provide evi-
dence of secondary packaging elements. We have also
related deficits in RNA packaging and dimerization to
overall viral infectivity and replication capacity.
Results
RNA structural domains on both sides of the major splice 
donor regulate the efficiency and specificity of SIVmac239 
RNA packaging and dimerization
We have constructed a series of proviral mutants within
the leader of SIVmac239 (Fig. 1A and 1B) and have assessed
vRNA packaging efficiency through both replicate slot
blotting and multiplex RT-PCR experiments. We have also
determined the impact of these mutations on vRNA
dimerization by recovery of RNA from mature virions and
analysis on native Northern gels. A diagrammatic depic-
tion of the folding of several of these RNA structures is
shown in Fig 2.
RNA packaging
The results of Fig. 3 show the average of three slot-blotting
experiments conducted with viral supernatants normal-
ized on the basis of p-27CA content. Slot blots were
probed with radioactively labeled probes to measure
either full-length or total RNA content from lysed virions.
Relative RNA encapsidation was determined and by
amounts were quantified by molecular imaging. Multi-
plex RT-PCR as described previously [[13], see also Mate-Retrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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Nucleotide position of deletion mutations within the leader sequence and the secondary structure of SIVmac239 leader RNA Figure 1
Nucleotide position of deletion mutations within the leader sequence and the secondary structure of SIVmac239 
leader RNA. A. Denotes the size and nucleotide position of deletion mutations located upstream (pU) or downstream (pD) 
of the major SD. All nucleotide deletions are relative to the transcriptional initiation site (1+) based on the sequence of the 
wild type clone of SIVmac239 [50]. B. Secondary structure was adapted from published information [13, 51]. All hairpin motifs 
are labeled according to their putative function and/or after comparable elements encoded by HIV-1/HIV-2 leader sequences. 
The following motifs are shown in bold type: the putative DIS palindrome at position +417-422, the splice donor (SD) at posi-
tion +462, and the Gag initiation codon at position +533.
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rials and Methods], was also used to corroborate slot-
blotting data (not shown). The largest reduction in pack-
aging efficiency was observed in the constructs that
removed or disrupted the distal stem portion of SL1 (i.e.
mutants pU∆39, pU∆33, and pU∆19). This RNA-deficient
phenotype was localized to the nucleotide region of SL1
removed in pU∆19 (Fig 1. and 3A) as deletion of the
regions directly adjacent (i.e. pU∆14 and pU∆6) resulted
in modest or no significant decrease in packaging, respec-
tively. Analysis of RNA secondary structures was con-
ducted using M-Fold software [48] and indicated that the
pU∆39 and pU∆33 deletions resulted in abolition of both
SL1 and SL2. However, for mutant pU∆19, a more con-
servative refolding resulted in the loss of the GGUACC
DIS sequence from the apical loop of SL1 and loss of the
SL2 structure (Fig. 2).
We also conducted deletion analysis of RNA structural
domains downstream of the SD. The largest deletions (i.e.
pD∆60 and pD∆51) resulted in severely diminished pack-
aging. Thermodynamic analysis of these mutants was also
conducted using M-Fold software and revealed a loss of
the SL3 element and refolding of the SD loop, but conser-
vation of SL4 and the structural elements upstream of the
SD, even though the deletions were quite large (Fig. 2,
panel III). Packaging deficits through smaller deletions
mutants could then be localized to SL3 and SL4; the
impact of these deletions on RNA encapsidation was addi-
tive (Fig. 3).
We also considered the impact of these deletions on the
specificity of RNA encapsidation by quantifying vRNA
versus total encapsidated RNA ratios from virions recov-
ered from cell-free supernantants (Fig 3B). Relative pack-
aging efficiencies shown in Fig. 3 indicate that the total
amount of RNA incorporated into each mutant virus was
generally conserved; presumably these mutants also
incorporated significant amounts of spliced viral RNA.
Thermodynamic folding analysis of resolved RNA SIVmac239 leader structures Figure 2
Thermodynamic folding analysis of resolved RNA SIVmac239 leader structures. Shown are predicted free-energy 
minimized structures from the SIVmac239 wild-type leader (I.) and attenuated mutants pU∆19 (II.) and pD∆60 (III.) [51]. Fig. I, 
arrows labeled a, b, c, and d denote SL1, SL2, SL3 and SL4, respectively, in the SIVmac239 leader structures or their absence in 
deletion variants.Retrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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To ensure that packaging deficits were not the result of
diminished availability of cytoplasmic vRNA, we also con-
sidered cell-associated vRNA concentrations. Towards this
end, total RNA was recovered from lysates of transfected
COS-7 cells and normalized on the basis of p27-capsid Ag
present in cellular lysates. All experiments used the same
probe that measured full-length vRNA as in slot-blotting
analysis (see Materials and Methods). The cytoplasmic
viral RNA levels in each case did not significantly deviate
from those observed with wild-type virus (not shown).
RNA dimerization
As mentioned above, we also analyzed phenol-chloro-
form extracted vRNA by non-denaturing Northern analy-
sis for each of the viral mutants from this study to
determine their ability to incorporate viral RNA as a
dimer. (Fig. 4A) shows the relative contribution of nucleo-
tide sequences upstream of the major SD. For each of the
pU∆39, pU∆33, and pU∆19 mutants, no dimeric RNA
was present, even after the overloading (4×) of viral RNA
preparations onto non-denaturing gels. Of the smaller
deletions, both pU∆14 and pU∆6 were capable of dimer
formation.
The analysis of regions downstream of the major SD
showed that only the largest deletions, i.e. pD∆60 and
pD∆51, completely disrupted dimerization (Fig 4B). In
contrast, viral RNA recovered from most constructs har-
boring smaller intermediate deletions within this region
did not differ significantly from the wild-type dimer. One
exception was mutant pD∆19, which consistently showed
a reduction in the amount of packaged dimeric RNA.
In vitro work from other groups has implicated regions
upstream of SL1 as involved in the dimerization of HIV-2
RNA [31-33]. To examine this issue in SIV, we analyzed
three mutants employed in previous studies (i.e. SD1,
SD2, and SD3) deleted the of nucleotide regions +322-
344, +398-418, and +345-397 respectively [13]. Analysis
of purified RNA from the SD1 mutant (nt +322 to +344
directly adjacent to the PBS), showed no qualitative or
quantitative differences in RNA dimer formation, mobil-
ity, or encapsidation compared to wild-type virus in either
its native conformation or heat-denatured state (Fig. 4C).
Deletion of regions implicated in viral RNA packaging and 
dimerization result in diminished infectivity and viral 
spread that correlates with aberrant viral core morphology
The results of Fig. 5 show that all mutants displayed some
replication impairment in the CEMx174 cell line as meas-
ured by RT assay. Specifically, mutants' pU∆39, pU∆33,
and pU∆19 showed severely impaired replication. Over 6
Both genomic RNA packaging efficiency and specificity are compromised in SIVmac239 by mutations within the leader region Figure 3
Both genomic RNA packaging efficiency and specificity are compromised in SIVmac239 by mutations within the 
leader region. A. Analysis of viral RNA packaging was conducted in triplicate in COS-7 cells. Shown are results from purified 
viral RNA preparations that were normalized on the basis of p27-CA ELISA. RNA packaging of various mutant constructs as a 
percent average of WT virus. The bars of the first lane for each sample represent total incorporated viral RNA. The second 
bar for each lane represents incorporated full-length viral RNA. B. Shown at the bottom is percent specific incorporation as a 
ratio of that obtained with the wild type full-length genome.
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months of extended culture, both the pU∆39 and pU∆33
mutants consistently scored negative by RT assay, indicat-
ing that deletions within this region presented an insur-
mountable barrier to the recovery of productive viral
replication. The pU∆19 mutant did replicate, but this was
delayed until 50 days post-infection, only common prior
to which pU∆19 culture supernatants were consistently
RT negative. The appearance of this phenotype was repro-
ducible, due to compensatory reversion. Conversely, both
the pU∆14 and pU∆6 variants, involving deletions in
nucleotide regions +443-456 and +457-463, respectively,
exhibited only minor delays in viral replication (Fig. 5A).
The elimination of sequences downstream of the splice
donor (SD) site also resulted in impaired viral replication
in the CEMx174 line. The most significant deficits in rep-
lication resulted from deletions that removed the entire
sequence from just downstream of the SD to the gag initi-
ation codon, i.e. pD∆60 (∆+471-530) and, to a lesser
extent, pD∆51 (∆+481-531). Smaller deletions spanning
this region had relatively little impact on replication
kinetics. Of these smaller intermediate deletions, only
pD∆19 (∆+511-529) resulted in a significant delay in viral
replication kinetics (Fig. 5B).
We also evaluated the impact of these deletions on viral
replication capacity in PHA-stimulated rhesus PBMCs by
monitoring the production of SIV capsid protein (p27) in
culture supernatants. Under these conditions our results
(Fig. 5C) show that pU∆39, pU∆33 and pU∆19 were
severely replication impaired in primary cells. The pU∆14
and pU∆6 mutants were not significantly affected and
retained replication kinetics indistinguishable from wild
type virus. In rhesus PBMC, impaired replication was
most apparent in mutants pD∆60 and pD∆51 (Fig. 5D),
similar to that observed in the CEMx174 line. Slight
delays in viral replication were observed for the smaller
deletions within this region, with generally similar data
obtained from both primary cells and cell lines.
The infectivity of these mutants was assessed using the
endpoint dilution method (TCID50) in CEMx174 cells
(see Materials and Methods). The results of Fig. 6A show
that infectiousness of viral leader mutants was impaired
by mutations on both sides of the major SD. Deletions
Non-denaturing Northern analysis of SIV RNA Figure 4
Non-denaturing Northern analysis of SIV RNA. Non-denaturing analysis of intra-virion RNA from transient transfec-
tions of mutant clones. Viral genomic RNA was isolated from virus particles after transfection of COS-7 cells with wild type or 
mutant plasmids. The relative mobility of dimers (D) and monomers (M) in 0.90% agarose are indicated. The plus (+) denotes 
the addition of RNase to preparations prior to electrophoresis. A. Shows non-denaturing RNA preparations from deletion 
mutants encompassing the region from nt +426 - +465. B. Shows non-denaturing RNA preparations from mutants encompass-
ing the nt region +473 - +480. C. RNA preparations from mutants encompassing the region directly adjacent to the PBS, i.e. 
SD1, SD2, and SD3 deleted the of nucleotide regions +322-344, +398-418, and +345-397 respectively [13]. The adjacent panel 
shows thermal denaturing analysis of the SD1 mutant (∆+322 - +344), comprising a 23-nucleotide deletion upstream of SL1 in 
comparison to dimer extracted from the wild-type virions.
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between nucleotide +424 to +462 had the most dramatic
effect on viral infectivity, resulting in a >3 log reduction
for the mutants pU∆39, pU∆33 and pU∆19 compared
with wild-type infectivity. Consistent with the replication
experiments described above, the mutant pU∆14 dis-
played insignificant reductions in viral infectivity and
pU∆6 was unaffected.
In the region downstream of the SD, (i.e. nt +471 to
+530), the mutants' pD∆60 and pU∆51 exhibited moder-
ately diminished infectiousness. Again, consistent with
that described above, the mutant pD∆19 displayed a
modest but significant reduction in infectivity, while the
remaining mutants were not compromised.
To determine the impact of deletion mutagenesis within
the SIV leader region on gag expression, particle forma-
tion, and viral maturation, COS-7 cells were transfected
with either wild type or mutant constructs. Virus contain-
Replication kinetics of various mutant constructs in CEMx174 cells and primary rhesus PBMC Figure 5
Replication kinetics of various mutant constructs in CEMx174 cells and primary rhesus PBMC. Cells were 
infected with 10 ng viral equivalents and viral replication was monitored by RT assay of culture supernatant at multiple time 
points. Mock denotes infection with heat-denatured wild-type virus. All replication experiments were conducted in triplicate. 
A. Representative growth curves of viruses deleted between the DIS and the SD (i.e. nt +424-462) in CEMx174 cells. B. Repli-
cation of viruses deleted between the SD and the Gag AUG (nt +471-530) in CEMx174 cells. Viral replication was assessed in 
activated rhesus PBMCs using viral inocula normalized on the basis of p27-CA Ag. Growth curves were determined by p27-CA 
Ag ELISA of culture supernatant taken at multiple time points. All results are the average of duplicates. C. Growth curves of 
variants deleted within the nt region +424-462. D. Growth curves of variants deleted within the region +471-530. Mock infec-
tion denotes exposure of cells to heat-inactivated wild-type virus as a negative control. Note that the scales of the ordinates 
are logarithmic. The dashed line representing 0.01 ng of p27/ml indicates the threshold of sensitivity of the assay.
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Analysis of protein expression and viral core ultrastructure of wild type and mutant viral particles Figure 6
Analysis of protein expression and viral core ultrastructure of wild type and mutant viral particles. A. Viral rep-
lication analysis of mutated viruses TCID50 analysis of viral infectivity, scale of ordinate is logarithmic. B. Western analysis of 
wild type and mutant virus particles C. TEM of late (fixed 36 hr post-transfection) wild type and mutant particles were assessed 
and scored from multiple sections. Panel I, wild-type virus has typical size and core morphology. Panel II, the pU∆19 mutant 
shows diminished production of viral particles, with altered core placement and morphology. Panel III, shows the pD∆60 
mutant; virus particle release less affected; particle condensation to a mature state is impaired. Bar size is .5 µM.
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ing culture supernatants were first clarified then pelleted
by ultracentrifugation through a 20% sucrose cushion.
The Western analysis of upstream leader mutants revealed
that total production of mature p27-CA protein was
severely diminished in the mutants deleted of leader
regions both up and downstream of the SD. This appeared
to be the result of a block in the proteolytic processing of
Pr55Gag protein. This phenotype was prominent in the
Western analysis of deletions within SL1 (pU∆39, pU∆33
and pU∆19), and was manifest as an accumulation of the
first and second cleavage intermediates (shown in Fig.
6B). Similar results were observed for the pD∆60 and
pU∆51 mutants, both displaying an accumulation of
intermediate processing products.
To further characterize this phenotype, we examined cell-
free virus particles by transmission EM (TEM) 36 hrs after
the transfection of COS-7 cells with wild type or mutant
proviral constructs. Multiple sections of stained cell prep-
arations were scanned by TEM and approximately 100
particles were scored for each virus mutant (see Fig. 5C).
Wild-type constructs (Fig. 6C, panel I) resulted in the pro-
duction of particles of typical morphology and dimension
(≈ 100 nm average) and condensed conical cores were
observed in >85% of particles with the remainder being of
immature morphology.
In contrast, both pU∆19 and pD∆60 showed diminished
particle production in conjunction with abnormalities in
the viral core (Fig. 6C, panel II and III respectively); these
were represented as either an immature-like core pheno-
type or grossly atypical core morphology.
Discussion
We have demonstrated that RNA elements on both sides
of the SD are critical to the viral lifecycle. Not only are
these specific elements required for both the efficiency
and specificity of vRNA encapsidation, both are important
in regard to the dimerization of vRNA. We have shown
that these vRNA deficits are linked with perturbations in
Pr55Gag processing, which ultimately disrupt viral core
architecture resulting in diminished viral infectivity and
replication.
Studies describing RNA packaging in HIV-1 or HIV-2 have
shown that the 5' proximal stem of SL1 interacts directly
with NC protein during the encapsidation process
[28,37]. However, deletions removing the upstream side
of the DIS stem, from both HIV-1 and SIV mutants,
resulted only in modest replication deficits compared to
the severely impaired replication of mutants harboring
nucleotide deletions to the distal side of SL1. In this study,
not only did the SL1-pU∆19 mutant display more than an
84% reduction in packaged vRNA but the comparative
decrease in infectivity was greater than 100-fold. Similar
observations have been reported regarding deletion of the
equivalent region of HIV-1 (∆+424-442) [28].
Although other groups have reported that the region
flanking SL1 (between SL1 and the SD) harbors the criti-
cal upstream packaging determinant, our results show
that SL1 acts as the primary cis-encapsidation determi-
nant. Discrepancy may be due to the specific nucleotide
deletions that were generated, or partially reflect the dif-
ferent methods used. However, as mentioned, we used
two independent methods to confirm packaging in addi-
tion to confirmation by non-denaturing Northern analy-
sis. Importantly, the analysis of viral mutants harboring
deletions proximal to SL1 (pU∆14 and pU∆6) had no sig-
nificant effect on viral infectivity or de novo replication
kinetics in CEMx174 lines or in rhesus PBMC. Yet, the
pU∆14 mutant was found to reduce vRNA packaging by
approximately 40% perhaps indicating that the secondary
structure of this element may be more critical than the loss
of primary sequence in regard to its function. Thus, the
primary role of this element may be as a part of an
extended DLS structure, rather than solely as a cis-packag-
ing element.
In regard to vRNA packaging, the nucleotide region down-
stream of the SD appears to play a secondary role relative
to regions located upstream of the major SD. The most
dramatic defects on packaging were observed when the
entire terminal 3' leader sequence was deleted (in the
mutant pD∆60 or pD∆51). Surprisingly, even these large
deletions failed to completely abrogate genome packaging
in SIVmac, contrary to the discrete packaging elements
described for simple retroviruses [2]. We used a series of
smaller targeted deletions to establish a specific role for
each of the stem-loop elements downstream of the SD.
We found that packaging specificity could be ascribed in a
roughly additive fashion to the smaller deletions disrupt-
ing either the SL3 or SL4 element.
Collectively, these data show a multipartite contribution
of RNA-leader sequences in SIV vRNA encapsidation, sim-
ilar to HIV-1. However, the importance of these domains
in regard to vRNA packaging appears to be reversed in ori-
entation compared to SL1 and the Ψ core of HIV-1 [2,4].
While RNA domains on both sides of the SD act in concert
to selectively incorporate full-length genomic transcripts,
we have ascribed the largest single contribution to SL1,
whereas both SL3 and SL4 together provide a significant
degree of specificity. Accordingly, we have denoted SL1
(Ψ1) as the major determinant and SL3 and SL4 as sec-
ondary elements (Ψ2, Fig. 1B). In parallel with HIV-1, it is
probable that accessory packaging elements exist else-
where within the untranslated leader region and possibly
within other coding regions as well [2]. For instance, theRetrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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presence of a functional intron within the SIV/HIV-2 R-U5
region of the UTR, a novel element for lentiviruses, could
afford an additional level of regulation of packaging of
genomic length RNA [21,38]. The presence of packaging
determinants within coding regions has also been estab-
lished for other retroviruses [2].
In regard to RNA dimerization, our non-denaturing
Northern analysis has shown that the leader regions
involved in dimerization are immediately proximal to the
major splice donor. The results presented here are in
agreement with the previous studies of HIV-1 [24,25,39]
and HIV-2 [32].
Whether vRNA encapsidation in HIV or SIV preferentially
occurs with a single vRNA strand or as a "dimer" com-
posed of two full-length vRNA molecules has not been
completely elucidated. In the case of MMLV and MLV,
recent work has strongly favored the latter notion, and
dimerized RNA has been show to be a necessary step prior
to encapsidation [40,41]. In the case of HIV-1, the abso-
lute requirement for dimeric vRNA in mature virions may
be dispensable as HIV-1 variants containing only single
genomes have been shown to be capable of undergoing
replication [6,42]. Other studies using SL1 deficient HIV
mutants indicated that the necessity for intravirion dimer-
ization may be target cell specific, or facilitated by func-
tional redundancy elsewhere within the viral genome
[26,43].
Disrupted phenotypes exhibiting or laterally displaced
cores were observed for several of our SIV mutants (Fig.
6). Several studies have supported the notion that viral
RNA plays an important structural role in viral core forma-
tion and stability during viral budding and morphogene-
sis [26,44,45]. We have also demonstrated a relationship
between viral core formation and deficits in RNA dimeri-
zation and altered Pr55 Gag processing, ultimately impact-
ing replication capacity and viral infectivity.
Similar observations have been reported for HIV-1 where
alterations of the "normal" vRNA compliment resulted in
morphological anomalies [46,47]. Forced evolutionary
studies of SL1 deficient variants of HIV-1 have shown a
direct role for the DIS/KLD with multiple protein
domains of NC, as well as other regions of the Gag-poly-
protein [28]. The compensatory reversion of these HIV-
SL1 mutants led to wild-type levels of HIV-1 packaging,
but not RNA dimerization, and to modified interaction
within several regions of Gag, including the p2 protein
[5,8,9].
In sum, the elimination of structures on either side of the
SD in SIV yields a replication-impaired phenotype, which
is attributable to blocks in RNA encapsidation and dimer-
ization.
Materials and methods
Construction of recombinant provirus
We used PCR-based mutagenesis and conventional clon-
ing techniques [48] to generate all deletion mutants; Pfu
polymerase was used for all PCR reactions. A full-length
infectious clone of SIV, SIVmac239 was used as a template to
construct all deletion mutants [13]. Briefly, the region
between the NarI and BamHI sites in SIVmac239  was
replaced by recombinant PCR fragments to generate all
mutant constructs (Figure 1). For construction of the
mutants upstream of the major SD, namely pU∆39,
pU∆33, and pU∆19, primer pairs pU∆39/pSgag, pU∆33/
pSgag1, and pU∆19/pSgag1 (Table 1) were used to gener-
ate deletion fragments that were purified, digested with
KpnI/BamHI, and ligated with a corresponding EcoRI/
BamHI fragment from the wild-type vector. The resulting
fragment was digested with EcoRI and BamHI and
inserted into the SIVmac239 clone. For the construction of
mutants' pU∆14 through pD∆8, a first round PCR was
performed using consecutive primers paired with the
primer SU5. For the mutants downstream (pD) of the
major SD i.e. pD∆60 through pD∆8 (Table 1), a first-
round PCR was performed using consecutive primers
paired with the primer SU5. The resultant fragments were
used as mega-primers paired with the Sgag1 primer to
generate the required deletion fragments that were then
used to replace the NarI/BamHI fragment from the wild-
type clone. The validity of all constructs was confirmed by
sequencing. Nucleotide designations are based on pub-
lished sequences; the transcription initiation site corre-
sponds to position +1.
RNA slot-blotting and RT-PCR
For analysis by slot blotting, viral RNA was isolated from
purified virus recovered from transient transfection
assays, clarified, and subsequently purified through a 20%
sucrose cushion. Virus pellets were re-suspended in TE
buffer and digested with DnaseI to remove potential plas-
mid contamination. Sample RNA was purified and then
analysed as per Northern analysis described below, using
the Scheicher and Schuell Minifold II slot-blotting system.
The slot-blot analysis of cellular RNA was also conducted
in parallel. Briefly, transfected COS-7 cells were washed
twice with cold phosphate-buffered saline and lysed with
NP-40 lysis buffer [45]. The cellular RNA within lysates
was incubated in the presence of proteinase K (100 µg/
ml) for 20 min at 37°C in the presence of 50 U of DNAse
I. Phenol: chloroform purification consisted of two extrac-
tions in phenol: chloroform: isoamyl alcohol, then chlo-
roform. Viral RNA was then precipitated, washed in 70%
ethanol and stored at -80°C until required, at which time
samples were resuspended in TE buffer at 4°C. RNA wasRetrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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transferred to Hybond-N nylon membranes by vacuum
assisted slot blotting using a 20× concentration of sodium
chloride, sodium phosphate-EDTA buffer (SSPE). Mem-
branes were baked for 2 hrs at 80°C. Probes were prepared
by digestion of the full-length proviral clone of
SIVmac239[13], and purification of either the NdeI-BstIIE
fragment (from U5 to RT region) to assess total virion
RNA content, or by, using a BstIIE double digestion frag-
ment (RT region only) to hybridize with genomic viral
RNA. Probes were radioactivity labelled with δ-P32-ATP by
nick-translation following standard manufacturer's proto-
cols (Roche, Indianapolis, IN, USA) and used in standard
hybridization reactions. Relative amounts of products
were quantified by molecular imaging (BIO-RAD Imag-
ing). RNA encapsidation was determined on the basis of
three different reactions, and calculated with wild type
virus levels arbitrarily set at 1.0.
To study packaging of viral genomic RNA, viral RNA was
isolated using the QIAamp viral RNA mini kit (QIAGEN)
from equivalent amounts of COS-7 cell-derived viral
preparations (normalized by SIV p27 antigen). RNA sam-
ples were treated with RNase-free DNase I at 37°C for 30
min to eliminate potential plasmid DNA contamination;
followed by inactivation by incubation at 75°C for 10
min. The viral RNA samples were quantified using the
Titan One Tube RT-PCR system (Boehringer Mannheim,
Montreal, Quebec, Canada). The primers sg1 and sg2 were
used to amplify a 114-bp fragment representing full-
length viral RNA. The primer sg2 was radioactively labeled
with δ-P32-ATP in order to visualize PCR products. Equiv-
alent RNA samples, based on p27 antigen levels, were
used as templates in an 18-cycle RT-PCR. The products
were fractionated on 5% polyacrylamide gels and exposed
to X-ray film. Relative amounts of products were quanti-
fied by molecular imaging (BIO-RAD Imaging). RNA
encapsidation was determined on the basis of four differ-
ent reactions, and calculated with wild type virus levels
arbitrarily set at 1.0.
Northern analysis
Culture fluids from transfected COS-7 cells were collected
and clarified using a Beckman GS-6R bench centrifuge at
3,000 rpm for 30 min at 4°C. Viral particles were further
purified through a 20% sucrose cushion at 40,000 rpm for
1 hour at 4°C using a SW41 rotor in a Beckman L8-M
ultracentrifuge. Viral pellets were first dissolved in Tris-
EDTA (TE) buffer, then in lysis buffer containing protein-
ase K (100 µg/ml) and yeast tRNA (100 µg/ml). Samples
were incubated for 20 min at 37°C, in the presence of 50
U of DNAse I, followed by two extractions first in phenol:
chloroform: isoamyl alcohol, then chloroform. Viral RNA
was then precipitated, washed in 70% ethanol and stored
at -80°C until required, at which time samples were resus-
pended in TE buffer at 4°C. RNA was then analysed by
non-denaturing electrophoresis on 0.9% agarose gels in
1× Tris-Borate-EDTA (TBE) running buffer for 4 hrs at
4°C. Products were subsequently denatured in 50 mM
NaOH and equilibrated in 200 mM Na-acetate. Following
electrophoresis, RNA was transferred to Hybond-N nylon
membranes by capillary blotting using a 20× concentra-
tion of SSPE buffer. Membranes were baked for 2 hrs at
Table 1: Primers utilized in these experiments
Name Sequence Locationa
pU∆39 5'-gtcggtacca/caggtaagtgcaacac-3' +1189-1254
pU∆33 5'-gtcggtacca/cggttgcaggtaagtgc-3' +1189-1249
pU∆19 5'-gtcggtacca/gaggaagaggcctccggttgc-3' + 1189-1238
pU∆14 5'-gcacttacctgcaaccg/tcccgctcctcacgcc-3' +1216-1254
pU∆6 5'-gtgttgcacttacctg/gaggcctcttcctctcc-3' +1203-1249
pD∆60 5'-ggagtttctcacgcccatct/cttacctgcaaccggag-3' +1230-1326
pD∆51 5'-ggagtttctcacgcccatctc/gtgttgcacttacctgc-3' +1238-1326
pD∆12 5'-cccttcctggataaaagacagc/gtgttgcacttacctgc-3' +1238-1288
pD∆19 5'-ggagtttctcacgcccatctc/cttcctggataaaagacagc-3' +1267-1326
pD∆20 5'-ccactctatcttattaccc/
tatttcttttttgtgttgcacttacctgcaac-3'
+1229-1305
pD∆8 5'-cctggataaaagacagctatttctttttt/
cttacctgcaaccggagg-3'
+1226-1283
Sgag1 5'-gcaaccccagttggatccatctcctgt-3' +1348-1322
su5 5'-aagctagtgtgtgttcccatctc-3' +175-197
Senf 5'-ggcttgagctcactctcttgtgag-3' +8705-8728
Sg 5'-cttccctgacaagacggag-3' +567-549
sg1 5'-gaagcatgtagtatgggcag-3' +627-646
sg2 5'-ggcactaatggagctaagaccg-3' +746-725
su3 5'-ccggaagggatttattacagtg-3' -518-497
su3-1 5'-ggctggctatggaaattagtccc-3' -390-367
a Location of the primer is relative to the transcription initiation site (+1)Retrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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80°C. Probes were prepared by digestion and purification
of the NdeI-BstE III fragment excised from the SIVmac239
plasmid. These were recovered by gel purification and
labelled with δ-P32-ATP by nick-translation following
standard protocols (Roche, Indianapolis, IN, USA). The
denaturing Northern analysis of cellular RNA was also
conducted in parallel. RNA extraction was carried out sim-
ilar to that described for slot blotting above. The cellular
RNA within extracted from lysates was normalized on the
basis of p27-Ca antigen present in cellular lysates. Total
cellular RNA preparations, i.e. equivalent volumes of
RNA, were also run on 1% ethidium bromide (EtBr)
stained gels as an internal control for total RNA and 28S
and 18S ribosomal RNAs. Probes were prepared as
described above Probes were labelled by nick-translation
following standard manufacturer's protocols (Roche,
Indianapolis, IN, USA) and used in standard hybridiza-
tion reactions.
Cell culture and transfection
COS-7 cells were maintained in DMEM medium supple-
mented with 10% heat-inactivated fetal bovine serum. All
media and sera were purchased from GIBCO Inc. (Burl-
ington, Ontario, Canada). CEMx174 cells were main-
tained in RPMI-1640 medium supplemented with 10%
heat-inactivated fetal bovine serum. Monkey PBMCs were
isolated from the blood of healthy rhesus macaques
(Macaca Mulatta), purchased from L.A.B. Pre-Clinical
Research International Inc., Montreal, Quebec. All pri-
mates were housed in accordance with accredited labora-
tory care standards. All donor macaques were
serologically negative for simian type-D retrovirus (SRV-
1), simian T-cell lymphotrophic virus type-1 (STLV-1),
and simian foamy virus (SFV-1) at the time of blood col-
lection.
Primate PBMCs were ficoll-purified followed by phytohe-
magglutinin (PHA) stimulation for 3 days, then main-
tained in RPMI-1640 medium supplemented with 10%
heat-inactivated fetal bovine serum and 20 U/ml IL-2.
Molecular constructs were purified using a Maxi Plasmid
Kit (QIAGEN Inc. Mississauga, Ontario, Canada). COS-7
cells were transfected using the above constructs with
lipofectamine 2000 reagent (GIBCO, Burlington,
Ontario, Canada). Virus-containing culture supernatant
was harvested at 48 h post-transfection and clarified by
centrifugation for 30 min at 4°C at 3,000 rpm in a Beck-
man GS-6R centrifuge. Viral stocks were passed through a
0.2 µm filter and stored in 0.5 ml or 1 ml aliquots at -
80°C. The concentration of p27 antigen in these stocks
was quantified using a Coulter SIV core antigen ELISA
assay (Immunotech Inc., Westbrook, ME, U.S.A.).
Virus replication in CEMx174 cells and rhesus macaque 
PBMCs
To initiate infection, viral stocks were thawed and treated
with 100 U of DNase I in the presence of 10 mM MgCl2 at
37°C for 0.5 h to eliminate any residual contaminating
plasmid DNA prior to inoculation of cells. Infection of
CEMx174 cells was performed by incubating 106 cells
with 10 ng of viral p27 antigen equivalent for 2 hrs at
37°C. Infected cells were then washed twice with phos-
phate-buffered saline and re-suspended in fresh supple-
mented RPMI-1640 medium. Cells were split at a ratio of
1:3, twice per week. Supernatants were routinely moni-
tored for virus production by reverse transcriptase (RT)
assay.
Virus infectivity (TCID50) was determined by infection of
CEMx174 cells as previously described [49]. Results were
calculated by the method of Reed and Muensch.
Virus replication was also assessed in rhesus PBMCs.
Briefly, 4 × 106 activated rhesus macaque PBMCs were
infected with SIV stocks containing 10 ng of p27-CA
equivalent at 37°C for 2 hours; the cells were then washed
extensively to remove any remaining virus. Cells were
maintained in 2 ml of culture medium as described above,
and fresh stimulated PBMCs were added to the cultures at
weekly intervals. Virus production in culture fluids was
monitored by both RT assay and SIV p27 antigen capture
assay (Coulter Immunotech Inc., Westbrook, ME, U.S.A.).
Western analysis of viral protein
At 48 hrs post-transfection, virus containing supernatants
from COS-7 transfected cells were collected and clarified
at 3000 rpm for 30 min. at 4°C in a GS-6R Beckman cen-
trifuge. Virus was further purified by pelleting through a
20% sucrose cushion by ultracentrifugation at 35000 rpm
in a Beckman ultracentrifuge for 1 hr at 4°C. Cells were
washed 2× in cold PBS and lysed by the addition of buffer
containing 1% Nonidet P-40, 50 mM Tris-CL (pH 7.4),
150 mM NaCl, 0.02% sodium azide, and a cocktail of pro-
tease inhibitors (Roche, Laval, Quebec, Canada). Virus
was normalized on the basis of p27-CA protein present in
supernatants or cell lysates. Both pelleted virus and cellu-
lar lysates were subject to Western blotting following
standard protocols [45] with monoclonal antibodies
directed at SIV p27-CA antigens (Fitzgerald industries, MA
USA).
Electron microscopy
Viral ultra-structure for the described mutant viruses was
examined by transmission electron microscopy. Briefly,
COS-7 cells transfected with wild type or mutant SIV con-
structs were fixed 48 hours post-tranfection in 2.5% glu-
taraldehyde/phosphate buffered saline followed by a
secondary fixation of lipids in 4% osmium tetroxide. Sam-Retrovirology 2006, 3:96 http://www.retrovirology.com/content/3/1/96
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ples were routinely processed and serially dehydrated, and
subsequently embedded in epon under vaccum. Thin-sec-
tioned samples were stained with lead citrate and uranyl
acetate and visualized at 80 KeV using a JEOL JEM-2000
FX transmission electron microscope equipped with a
Gatan 792 Bioscan wide-angle 1024 × 1024 byte multi-
scan CCD camera.
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